Literature DB >> 19528487

Demethylation of the CD133 gene is frequently detected in advanced colorectal cancer.

Kenji Hibi1, Makiko Sakata, Yo-Hei Kitamura, Kazuma Sakuraba, Atsushi Shirahata, Tetsuhiro Goto, Hiroki Mizukami, Mitsuo Saito, Kazuyoshi Ishibashi, Gaku Kigawa, Hiroshi Nemoto, Yutaka Sanada.   

Abstract

BACKGROUND: Recently, it has been reported that colorectal carcinoma is created and propagated by a small number of undifferentiated tumorigenic CD133(+) cells. Furthermore, it has been reported that CD133 expression is directly regulated by epigenetic modifications. Therefore, it is possible that CD133 expression by gene demethylation is related to colorectal carcinogenesis.
MATERIALS AND METHODS: The methylation status of the CD133 gene was examined in primary carcinomas and the corresponding normal tissues derived from 48 patients with colorectal cancer using quantitative methylation-specific PCR (qMSP) and the correlation between the methylation status and the clinicopathological findings was evaluated.
RESULTS: Demethylation of the CD133 gene was detected in 19 out of the 48 (40%) primary colon carcinomas, suggesting that the demethylation of CD133 is frequently observed in colorectal carcinomas. The clinicopathological data were correlated with the demethylation results. A significant difference was observed in the maximal tumor size (p=0.0222). Moreover, a trend was shown toward preferentially developing lymph node metastasis in demethylated tumors (p=0.214).
CONCLUSION: CD133 was more frequently demethylated in advanced colorectal carcinomas.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19528487

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Correlation of aberrant expression of CD133 with FHIT and malignant phenotype of colorectal adenocarcinoma.

Authors:  Hong Li; Po Zhao; Yang Lu; Yali Lu
Journal:  Int J Colorectal Dis       Date:  2012-02-09       Impact factor: 2.571

2.  Promoter hypermethylation and loss of CD133 gene expression in colorectal cancers.

Authors:  You-Kyung Jeon; Sung-Hee Kim; Seung-Ho Choi; Kyung-Hee Kim; Byong-Chul Yoo; Ja-Lok Ku; Jae-Gahb Park
Journal:  World J Gastroenterol       Date:  2010-07-07       Impact factor: 5.742

3.  Major Protein of Carcinoembryonic Antigen Gene Family - CD66c, A Novel Marker in Colon Carcinoma.

Authors:  Suma M Nataraj; Chaitra Linganna Prema; Manjunath Gubbanna Vimalambike; Sheeladevi Chandakavadi Shivalingaiah; Shivakumar Sundaram; Anjali Pradeep Kumar; Ananda Kuruvatti Math; Akila Prashant
Journal:  J Clin Diagn Res       Date:  2016-02-01

4.  Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells.

Authors:  Anne M Friel; Ling Zhang; Michael D Curley; Vanessa A Therrien; Petra A Sergent; Sarah E Belden; Darrell R Borger; Gayatry Mohapatra; Lawrence R Zukerberg; Rosemary Foster; Bo R Rueda
Journal:  Reprod Biol Endocrinol       Date:  2010-12-01       Impact factor: 5.211

5.  Prognostic significance of stem cell marker CD133 determined by promoter methylation but not by immunohistochemical expression in malignant gliomas.

Authors:  Xing Wu; Fenlang Wu; Dongwen Xu; Tao Zhang
Journal:  J Neurooncol       Date:  2016-01-12       Impact factor: 4.130

6.  Inhibition of CREB binding protein-beta-catenin signaling down regulates CD133 expression and activates PP2A-PTEN signaling in tumor initiating liver cancer cells.

Authors:  Yuanyuan Tang; Joshua Berlind; Nirmala Mavila
Journal:  Cell Commun Signal       Date:  2018-03-12       Impact factor: 5.712

7.  CD133: a stem cell biomarker and beyond.

Authors:  Zhong Li
Journal:  Exp Hematol Oncol       Date:  2013-07-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.